United Kingdom · Question · Written question
HL HL13668
Liothyronine
Introduced
24 February 2021
Last action
4 March 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
4 March 2021
Summary
To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 17 February (HL13177), whether an intervention under the Health Service Medical Supplies (Costs) Act 2017 has taken place to control the cost of Liothyronine (T3); and if no
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
24 February 2021
Written question
To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 17 February (HL13177), whether an intervention under the Health Service Medical Supplies (Costs) Act 2017 has taken place to control the cost of Liothyronine (T3); and if no
Source: Lords
4 March 2021
Answer
No such intervention has taken place. Several marketing authorisations have been granted for liothyronine since 2016 and the reimbursement price has been reducing as a direct response to more competition in the market.
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-02-24/HL13668
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1289365
- uk · wq-1289365 · source updated 4 March 2021